Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab in Head and Neck Squamous Cell Carcinoma (DAHANCA 19)
NCT00496652Phase 3Completed
- Sponsor
- Danish Head and Neck Cancer Group
- Start
- Nov 2007
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of zalutumumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Danish Head and Neck Cancer Group. Started Nov 2007; status: completed.
02
Drugs
zalutumumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00496652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496652.